Andera Partners | WebDisclosure

Basculer en Français

10965	Companies
240117	Keywords
168876	Articles
129205	Press releases

Home
Companies
Andera Partners

PRESS RELEASE

published on 10/22/2025 at 09:00, 10 months 20 days ago

Ipsen to acquire ImCheck Therapeutics, in Andera Partners’ portfolio, expanding its leadership in oncology, strengthening its pipeline
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology by acquiring all shares of ImCheck. Anticipated acquisition focuses on ICT01 program for acute myeloid leukemia. Transaction details and advisors highlighted

Acquisition Oncology Ipsen ImCheck Therapeutics ICT01
BRIEF

published on 10/16/2025 at 11:10, 10 months 26 days ago

Andera Partners co-dirige une levée de fonds de série A de 105 millions d'euros pour Adcytherix

Investissement Andera Partners Traitements Contre Le Cancer Adcytherix BioDiscovery 7
BRIEF

published on 10/16/2025 at 11:10, 10 months 26 days ago

Andera Partners Co-Leads €105 Million Series A for Adcytherix

Investment Andera Partners Cancer Treatments Adcytherix BioDiscovery 7
PRESS RELEASE

published on 10/16/2025 at 11:05, 10 months 26 days ago

Andera Partners co-leads €105 million Series A round for Adcytherix, its first investment from the BioDiscovery 7 fund
Andera Partners co-leads €105 million Series A funding round for Adcytherix, marking the first investment from BioDiscovery 7 fund to advance novel ADC programs for cancer treatment

Andera Partners ADC Series A Adcytherix BioDiscovery 7
BRIEF

published on 10/15/2025 at 11:15, 10 months 27 days ago

Andera Partners Commits to Tubulis' €308 Million Series C for ADC Development

Series C Financing Andera Partners Tubulis ADC Development Clinical Expansion
BRIEF

published on 10/15/2025 at 11:15, 10 months 27 days ago

Andera Partners s'engage dans la série C de Tubulis, d'un montant de 308 millions d'euros, pour le développement d'ADC

Andera Partners Tubulis Développement ADC Financement De Série C Expansion Clinique
PRESS RELEASE

published on 10/15/2025 at 11:10, 10 months 27 days ago

Andera Partners Reinvests in Tubulis’ €308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline
Andera Partners reinvests in Tubulis' €308 million Series C financing to accelerate clinical development of lead ADC candidate TUB-040 and expand pipeline, attracting top-tier investors

Series C Financing Clinical Development Andera Partners Tubulis ADC Candidate
BRIEF

published on 06/12/2025 at 10:05, 1 year 2 months ago

Andera Partners Expands Mezzanine Sponsorless Strategy with Key Appointments

Andera Partners Strategic Appointments European Markets International Development Mezzanine Sponsorless
BRIEF

published on 06/12/2025 at 10:05, 1 year 2 months ago

Andera Partners élargit sa stratégie de financement mezzanine sans sponsor avec des nominations clés

Développement International Andera Partners Marchés Européens Nominations Stratégiques Mezzanine Sans Sponsor
PRESS RELEASE

published on 06/12/2025 at 10:00, 1 year 2 months ago

Andera Partners increases international development of its Mezzanine Sponsorless business and announces two strategic appointments
Andera Partners expands Mezzanine Sponsorless business internationally with two strategic appointments, reinforcing European private financing strategy

Andera Partners Strategic Appointments International Development Mezzanine Sponsorless Private Financing

Accesswire

Published on 09/11/2026 at 17:00, 2 hours 12 minutes ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 2 hours 12 minutes ago

Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 15:25, 3 hours 47 minutes ago

Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 4 hours 12 minutes ago

Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 4 hours 42 minutes ago

AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 18:15, 56 minutes ago

CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:07, 1 hour 5 minutes ago

Holding(s) in Company
Published on 09/11/2026 at 18:06, 1 hour 5 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 09/11/2026 at 18:00, 1 hour 12 minutes ago

ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 18:00, 1 hour 12 minutes ago

ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL

Les Echos

Published on 09/11/2026 at 07:00, 12 hours 12 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 12 hours 12 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 12 hours 12 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 12 hours 12 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 23 hours 42 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE